蛋白激酶C-theta调解了对调节性T细胞功能的负面反
Alexandra Zanin-Zhorov1, Yi Ding, Sudha Kumari
1Molecular Pathogenesis Program, Helen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.
概括
蛋白激酶C-甲基 (PKC-甲基) 抑制了调节性T细胞 (Treg) 功能. 阻断PKC-β增强Treg活性,通过恢复Treg功能在炎症类细胞因子的存在,为炎症性疾病提供治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 炎症研究 炎症研究
背景情况:
- 调节性T细胞 (Tregs) 控制免疫反应,但被瘤缩因子-α (TNF-α) 抑制.
- 蛋白激酶C-甲基 (PKC-甲基) 对于效应性T细胞 (Teff) 激活至关重要.
- 之前,PKC-theta在Treg功能中的作用尚不清楚.
研究的目的:
- 研究PKC-theta在Treg功能中的作用及其与TNF-alpha的相互作用.
- 为了确定抑制PKC-theta是否可以恢复Treg活性.
主要方法:
- 研究了Treg免疫突触中的PKC-theta局部化.
- 在体外和体外模型中利用了PKC-甲基阻塞.
- 在TNF-alpha和疾病模型中评估Treg功能.
主要成果:
- PKC-theta被隔离离离Treg免疫突触.
- PKC-甲基阻塞增强了Treg介导的抑制.
- 抑制PKC-甲基受保护的Tregs从TNF-α诱导的失活.
- 在类风湿性关节炎患者中恢复Treg功能,在小鼠中改善结肠炎保护.
结论:
- PKC-甲基作为Treg功能的抑制剂.
- 准PKC-theta可以克服Tregs的炎症性细胞因子抑制.
- 抑制PKC-甲基是对炎症性疾病的一种有前途的治疗策略.
相关概念视频
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

